% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • terry_amln terry_amln Aug 26, 2013 10:08 AM Flag

    Genomic Health gaining fast in genomic testing...just wait till prostate

    Prolaris faces direct competition from Oncotype DX, the test provided by Genomic Health. In addition to checking the severity of prostate cancer, Oncotype DX is also approved for checking the severity of breast and colon cancer in the patient. Genomic introduced this test in May 2013, so Prolaris will have the first mover advantage. However, the additional features of Oncotype DX will bring in better returns for Genomic Health compared to Prolaris for Myriad Genetics.

    To develop the Oncotype DX prostate cancer test further, Genomic Health conducted research studies on more than 700 patients. In these studies, scientists analyzed genes in prostate cancer samples of these 700 patients. The development studies resulted in discovery of 81 genes from prostate cancer samples. These genes will go through additional research before moving on to clinical usage, which will help improve the Oncotype DX test in the future. These developments are enough to present strong headwinds for Prolaris. The additional features and developmental studies are popularity factors for the Oncotype DX test, and more than 19,000 physicians in over 70 countries ordered 375,000 Oncotype DX tests as of June 30, 2013.


    The flagship program BRACanalysis maintained the company's dominance for past ten years, and its legacy is expected to continue with myRisk. BRACanalysis is also being used currently as a companion test with Tesaro's niraparib. Prolaris is another key factor for Myriad Genetics, but the competitive pressure from Genomic Health is a headwind for Prolaris. These factors hint at a "hold" until Myriad Genetics makes any substantial moves.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
29.66-0.07(-0.24%)Oct 21 4:00 PMEDT